What is the Fiscal Year for Atossa Therapeutics?
Date: November 13, 2026
Atossa Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Seattle, Washington
Industry
Biotechnology
Stock Symbol
ATOS
Description
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a biopharmaceutical company developing innovative therapeutics to fight breast cancer, one of the most common and devastating diseases impacting women. Led by renowned physician-scientist Dr. Steven Quay, the Company has a powerful mission: to change the trajectory and outcomes of breast cancer. It is in active regulatory dialogue with the FDA to accelerate the development of its lead product candidate, (Z)-endoxifen, to reduce breast cancer incidence in high-risk women and in select treatment settings.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Atossa Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.